Talk to the Institute
Published mark

Arcus Biosciences, Inc.

NYSE: RCUS. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:eed78fab-8a67-4bbc-a621-d77f4e600d2e
SEC CIK
0001724521
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
Newest evidence
Apr 21, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Terry RosenSince Apr 21, 2026
Chair
Terry Rosen, Ph.D.
Independent
Not published8 directors published
Published claims
432 distinct sources
Evidence records
60 pinned
Source conflicts
0None open

Built from 2 distinct sources and 6 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

DIRECTOR APPOINTED

Andrew Perlman seat on Arcus Biosciences, Inc., effective 2026-04-21.

EffectiveEffective Apr 21, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Financial OfficerRichard B. Cassidy IIApr 2026currentSource reportedE4
Chief Financial OfficerRobert C. GoeltzApr 2026currentSource reportedE3
Chief Executive Officer and DirectorTerry RosenApr 2026currentSource reportedE3
Chief Executive Officer, Director and ChairmanThilo Schroeder, Ph.D.Apr 2026currentSource reportedE5
General CounselCarolyn TangNot capturedunknownSource reportedE2
Chief Operating OfficerJennifer JarrettNot capturedunknownSource reportedE2
PresidentJuan Carlos Jaen, Ph.D.Not capturedunknownSource reportedE2
Chief Medical OfficerRichard Markus, M.D., Ph.D.Not capturedunknownSource reportedE2
Chief Executive OfficerTerry Rosen, Ph.D.Not capturedunknownSource reportedE2

Board of directors

Evidence

8 directors published. Independence determinations are not published for every director.

DirectorStatusSinceCommitteesClaim
Andrew PerlmanIndependence not published2026Audit CommitteeSource reportedE3
David LaceyIndependence not published2026Compensation CommitteeNominating and Corporate Governance Committee, chairSource reportedE3
Dietmar BergerIndependence not published2025None publishedSource reportedE3
Kathryn FalbergIndependence not published2026Audit Committee, chairCompensation CommitteeSource reportedE3
Nicole LambertIndependence not published2026Compensation CommitteeNominating and Corporate Governance CommitteeSource reportedE3
Patrick MachadoIndependence not published2026Nominating and Corporate Governance CommitteeSource reportedE3
Terry RosenIndependence not published2017None publishedSource reportedE3
Yasunori KanekoIndependence not published2026Audit CommitteeCompensation Committee, chairSource reportedE3
Andrew Perlman, M.D., Ph.D.IndependentNot publishedNone publishedSource reportedE2
Antoni Ribas, M.D., Ph.D.IndependentNot publishedNone publishedSource reportedE2
David Lacey, M.D.IndependentNot publishedNone publishedSource reportedE2
Dietmar Berger, M.D., Ph.D.IndependentNot publishedNone publishedSource reportedE2
Johanna MercierIndependentNot publishedNone publishedSource reportedE2
Linda Higgins, Ph.D.IndependentNot publishedNone publishedSource reportedE2
Patrick Machado, J.D.IndependentNot publishedNone publishedSource reportedE2
Terry Rosen, Ph.D.Not independentChairNot publishedDirector and ChairmanSource reportedE2
Yasunori Kaneko, M.D.IndependentNot publishedNone publishedSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
Audit CommitteeKathryn FalbergKathryn Falberg, Andrew Perlman, Yasunori KanekoNot described in the published record
Compensation CommitteeYasunori KanekoYasunori Kaneko, David Lacey, Kathryn Falberg, Nicole LambertNot described in the published record
Director and ChairmanNot publishedTerry Rosen, Ph.D.Not described in the published record
Nominating and Corporate Governance CommitteeDavid LaceyDavid Lacey, Nicole Lambert, Patrick MachadoNot described in the published record
Committee RecordAudit Committee: Chair Kathryn Falberg; Members Kathryn Falberg (Chair); Andrew Perlman; Yasunori Kaneko
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_record:31
Committee AppointmentKathryn Falberg: chair, Audit Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:32
Committee AppointmentAndrew Perlman: member, Audit Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:33
Committee AppointmentYasunori Kaneko: member, Audit Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:34
Committee RecordCompensation Committee: Chair Yasunori Kaneko; Members Yasunori Kaneko (Chair); David Lacey; Kathryn Falberg; Nicole Lambert
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_record:35
Committee AppointmentYasunori Kaneko: chair, Compensation Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:36
Committee AppointmentDavid Lacey: member, Compensation Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:37
Committee AppointmentKathryn Falberg: member, Compensation Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:38
Committee AppointmentNicole Lambert: member, Compensation Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:39
Committee RecordNominating and Corporate Governance Committee: Chair David Lacey; Members David Lacey (Chair); Nicole Lambert; Patrick Machado
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_record:40
Committee AppointmentDavid Lacey: chair, Nominating and Corporate Governance Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:41
Committee AppointmentNicole Lambert: member, Nominating and Corporate Governance Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:42
Committee AppointmentPatrick Machado: member, Nominating and Corporate Governance Committee
Source reportedE6
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:committee_appointment:43

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerTerry Rosen, Chief Executive Officer and Director, from Apr 21, 2026
Source reportedE3
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:leadership_role:28
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingRCUS (NYSE)
Source reportedE1
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:security_listing:44
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameArcus Biosciences, Inc.
Source reportedE1
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:eed78fab-8a67-4bbc-a621-d77f4e600d2e:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
6 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    SEC DEF 14A 0001724521-26-000025
    sec def 14a. Published Apr 21, 2026. Retrieved Sep 12, 2026. Cited by 14 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    DEF 14A rcus-20260421.htm
    sec proxy. Published Apr 21, 2026. Retrieved Sep 2, 2026. Cited by 10 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    RCUS DEF 14A executive officers
    sec filing. Published Apr 21, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    RCUS DEF 14A executive officers
    sec filing. Published Apr 21, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    Audit Committee
    governance_people_committees. sec proxy. Cited by 13 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026
  • Andrew Perlman seat on Arcus Biosciences, Inc., effective 2026-04-21.
  • David Lacey seat on Arcus Biosciences, Inc., effective 2026-04-21.
  • Kathryn Falberg seat on Arcus Biosciences, Inc., effective 2026-04-21.
  • Nicole Lambert seat on Arcus Biosciences, Inc., effective 2026-04-21.
  • Patrick Machado seat on Arcus Biosciences, Inc., effective 2026-04-21.
  • Yasunori Kaneko seat on Arcus Biosciences, Inc., effective 2026-04-21.
  • Richard B. Cassidy II executive of Arcus Biosciences, Inc., effective 2026-04-21.
  • Robert C. Goeltz executive of Arcus Biosciences, Inc., effective 2026-04-21.
  • Terry Rosen executive of Arcus Biosciences, Inc., effective 2026-04-21.
  • Thilo Schroeder, Ph.D. executive of Arcus Biosciences, Inc., effective 2026-04-21.
  • Dietmar Berger seat on Arcus Biosciences, Inc., effective 2025-01-01.
  • Terry Rosen seat on Arcus Biosciences, Inc., effective 2017-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:eed78fab-8a67-4bbc-a621-d77f4e600d2e, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/arcus-biosciences-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership9
  4. Board17
  5. Committees4
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people24
  17. Subject and corrections6
  18. Evidence6
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:eed78fab-8a67-4bbc-a621-d77f4e600d2e
  • Cite this recordArcus Biosciences, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/arcus-biosciences-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Arcus Biosciences, Inc.Company
  • Richard B. Cassidy IIPerson
  • Robert C. GoeltzPerson
  • Terry RosenPerson
  • Thilo Schroeder, Ph.D.Person
  • Carolyn TangPerson
  • Jennifer JarrettPerson
  • Juan Carlos Jaen, Ph.D.Person
  • Richard Markus, M.D., Ph.D.Person
  • Terry Rosen, Ph.D.Person
  • Andrew PerlmanPerson
  • David LaceyPerson
  • Dietmar BergerPerson
  • Kathryn FalbergPerson
  • Nicole LambertPerson
  • Patrick MachadoPerson
  • Yasunori KanekoPerson
  • Andrew Perlman, M.D., Ph.D.Person
  • Antoni Ribas, M.D., Ph.D.Person
  • David Lacey, M.D.Person
  • Dietmar Berger, M.D., Ph.D.Person
  • Johanna MercierPerson
  • Linda Higgins, Ph.D.Person
  • Patrick Machado, J.D.Person
  • Yasunori Kaneko, M.D.Person
  • Sections
    OverviewArcus Biosciences, Inc.
  • MonitoringArcus Biosciences, Inc.
  • LeadershipArcus Biosciences, Inc.
  • BoardArcus Biosciences, Inc.
  • CommitteesArcus Biosciences, Inc.
  • Control and votingArcus Biosciences, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.